Higher Blood Vitamin C Levels are Associated with Reduction of Apolipoprotein E E4-related Risks of Cognitive Decline in Women: The Nakajima Study

Journal of Alzheimer's Disease : JAD
Moeko Noguchi-ShinoharaMasahito Yamada

Abstract

Antioxidants like vitamins C and E may minimize the risk for Alzheimer's disease. We examined whether vitamins C and E modify the apolipoprotein E (APOE) E4-related risks for developing cognitive decline. We conducted a population-based prospective study including Japanese residents aged 65 years from Nakajima, Japan. The participants received an evaluation of cognitive function and underwent blood tests including tests for vitamins C and E levels and APOE phenotypes. The APOE E4-by-gender-by-vitamin C or E interactions on developing cognitive decline were analyzed. Of 606 participants with normal cognitive function determined using a baseline survey (2007-2008), 349 completed the follow up survey between 2014 and 2016. In women with APOE E4, significantly reduced risk for cognitive decline was observed for the highest blood vitamin C concentration tertile [multivariate OR 0.10 (95% CI 0.01-0.93)] compared with the lowest tertile. In men without APOE E4, significantly reduced risk for cognitive decline was observed for the highest blood vitamin E concentration tertile [multivariate OR 0.19 (0.05-0.74)] as compared with the lowest tertile. Our results demonstrate significant beneficial effects of vitamins C and E in reducing the...Continue Reading

References

Nov 1, 1975·Journal of Psychiatric Research·M F FolsteinP R McHugh
Jan 1, 1987·Annals of the New York Academy of Sciences·P J GarryW C Hunt
Mar 9, 1996·BMJ : British Medical Journal·C R GaleC Cooper
Jun 1, 1997·Journal of the American Geriatrics Society·W J PerrigH B Stähelin
Dec 16, 1998·International Journal of Geriatric Psychiatry·S RivièreB Vellas
Jun 28, 2002·JAMA : the Journal of the American Medical Association·Marianne J EngelhartMonique M B Breteler
Jun 22, 2002·JAMA : the Journal of the American Medical Association·Martha Clare MorrisPaul A Scherr
Mar 29, 2003·The American Journal of Clinical Nutrition·Francine GrodsteinWalter C Willett
Jan 21, 2004·Archives of Neurology·Peter P ZandiUNKNOWN Cache County Study Group
Nov 10, 2004·Neurology·Kristine YaffeUNKNOWN Age-Related Eye Disease Study Research Group
Oct 30, 2007·Biochemical and Biophysical Research Communications·Shizu HigasaYasuo Kagawa
Feb 21, 2009·Proceedings of the National Academy of Sciences of the United States of America·Robert M KoffieTara L Spires-Jones
Apr 24, 2010·Journal of Neurochemistry·Ioannis DafnisAngeliki Chroni
Jul 14, 2010·Archives of Neurology·Elizabeth E DevoreMonique M B Breteler
Dec 15, 2010·European Journal of Nutrition·Alexandra HorskaMaria Dusinska
Jul 1, 2011·Science Translational Medicine·Joseph M CastellanoDavid M Holtzman
Oct 27, 2012·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Tadafumi HashimotoBradley T Hyman
Jun 6, 2013·British Journal of Cancer·H R HarrisA Wolk
Mar 14, 2014·Annals of Neurology·Andre AltmannUNKNOWN Alzheimer's Disease Neuroimaging Initiative Investigators
Apr 26, 2014·Nutrients·Fiona E HarrisonMaria Cristina Polidori
Apr 24, 2015·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·Y A KimC S Shin
Nov 20, 2015·The Journal of Nutrition·Sunni L MumfordEnrique F Schisterman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: APOE

Apolipoprotein E (APOE) polymorphic alleles are major genetic risk factors for Alzheimer's disease. Discover the latest research on APOE and other genetic determinants of Alzheimer's disease here.

ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.